Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease: A Case Report

Journal of Bone and Mineral Research

Volumn 33, Issue 3, 2018, Pages 534-539

  Bartko, Johann ^a   Roschger, Paul ^a   Zandieh, Shahin ^a   Brehm, Attila ^a   Zwerina, Jochen ^a   Klaushofer, Klaus ^a  

^a HANUSCH HOSPITAL   (Austria)

Author keywords

CROHN'S DISEASE; FGF23; FRACTURE; HYPOPHOSPHATEMIA; INFLAMMATORY BOWEL DISEASE; IRON INFUSION; OSTEOMALACIA

Indexed keywords

ADALIMUMAB; ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; IRON; MESALAZINE; PHOSPHATE; VITAMIN D; ZOLEDRONIC ACID;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY MASS; BONE BIOPSY; BONE DENSITY; BONE MARROW BIOPSY; BONE MASS; BONE MINERALIZATION; BONE MINERALIZATION DENSITY DISTRIBUTION; BONE PAIN; BONE TURNOVER; CASE REPORT; CHRONIC DISEASE; CLINICAL ARTICLE; CROHN DISEASE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMORAL NECK; FERRITIN BLOOD LEVEL; GAIT DISORDER; GASTROINTESTINAL HEMORRHAGE; HUMAN; HUMAN TISSUE; HYPOPHOSPHATEMIA; ILIAC CREST; IRON DEFICIENCY ANEMIA; IRON THERAPY; LABORATORY TEST; LOW BACK PAIN; LUMBAR SPINE; MALE; MEDICAL HISTORY; MICROCYTIC ANEMIA; MORPHOMETRY; OSSIFICATION; OSTEOBLAST; OSTEOID; OSTEOMALACIA; OUTPATIENT DEPARTMENT; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PHOSPHATE URINE LEVEL; SACROILIAC JOINT; SOCCER; STRESS FRACTURE; THORACIC SPINE; TRABECULAR BONE; URINARY EXCRETION; VITAMIN SUPPLEMENTATION; BIOPSY; BLOOD; BONE; DIAGNOSTIC IMAGING; DRUG EFFECT; GAIT; INFLAMMATORY BOWEL DISEASE; INTRAVENOUS DRUG ADMINISTRATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADMINISTRATION, INTRAVENOUS; ADULT; BIOPSY; BONE AND BONES; CALCIFICATION, PHYSIOLOGIC; FRACTURES, STRESS; GAIT; HUMANS; HYPOPHOSPHATEMIA; INFLAMMATORY BOWEL DISEASES; IRON; MAGNETIC RESONANCE IMAGING; MALE; PAIN; PHOSPHATES;

EID: 85034637884     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.3319     Document Type: Article

References (40)

1. Roschger P, Paschalis EP, Fratzl P, Klaushofer K. Bone mineralization density distribution in health and disease. Bone. 2008; 42(3):456–66.
2. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009; 94(7):2332–7.
3. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013; 28(8):1793–803.
4. Sato K, Shiraki M. Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. Endocr J. 1998; 45(4):431–9.
5. Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens. 2014; 23(4):411–9.
6. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19(3):429–35.
7. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008; 103(5):1182–92.
8. Bhandari S, Kalra PA, Kothari J, et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer(R)) compared with iron sucrose (Venofer(R)) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant. 2015; 30(9):1577–89.
9. Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 2013; 24(2):475–82.
10. Birgegard G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M. A randomized noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy: the PROFOUND trial. Pharmacotherapy. 2016; 36(4):402–14.
11. Bishay RH, Ganda K, Seibel MJ. Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature. Ther Adv Endocrinol Metab. 2017; 8(1–2):14–9.
12. Schaefer B, Wurtinger P, Finkenstedt A, et al. Choice of high-dose intravenous iron preparation determines hypophosphatemia risk. PLoS One. 2016; 11(12):e0167146.
13. Bager P, Hvas CL, Dahlerup JF. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br J Clin Pharmacol. 2017; 83(5):1118–25.
14. Ott SM. Histomorphometric measurements of bone turnover, mineralization, and volume. Clin J Am Soc Nephrol. 2008; 3 Suppl 3:S151–6.
15. Kulak CA, Dempster DW. Bone histomorphometry: a concise review for endocrinologists and clinicians. Arq Bras Endocrinol Metabol. 2010; 54(2):87–98.
16. Oostlander AE, Bravenboer N, Sohl E, et al. Histomorphometric analysis reveals reduced bone mass and bone formation in patients with quiescent Crohn's disease. Gastroenterology. 2011; 140(1):116–23.
17. Ward LM, Rauch F, Matzinger MA, Benchimol EI, Boland M, Mack DR. Iliac bone histomorphometry in children with newly diagnosed inflammatory bowel disease. Osteoporos Int. 2010; 21(2):331–7.
18. Recker RR, Weinstein RS, Chesnut CH 3rd, et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int. 2004; 15(3):231–7.
19. Bjornerem A. The clinical contribution of cortical porosity to fragility fractures. Bonekey Rep. 2016; 5:846.
20. Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis EP, Phipps R, Klaushofer K. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume. Calcif Tissue Int. 2007; 81(2):73–80.
21. Negri AL, Bogado CE, Zanchetta JR. Bone densitometry in a patient with hypophosphatemic osteomalacia. J Bone Miner Metab. 2004; 22(5):514–7.
22. Saghafi M, Azarian A, Hashemzadeh K, Sahebari M, Rezaieyazdi Z. Bone densitometry in patients with osteomalacia: is it valuable? Clin Cases Miner Bone Metab. 2013; 10(3):180–2.
23. Roschger P, Gupta HS, Berzlanovich A, et al. Constant mineralization density distribution in cancellous human bone. Bone. 2003; 32(3):316–23.
24. Zhao X, Zhou C, Chen H, et al. Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: a systematic review with network meta-analysis. Medicine (Baltimore). 2017; 96(11):e6378.
25. Dadoniene J, Miglinas M, Miltiniene D, et al. Tumour-induced osteomalacia: a literature review and a case report. World J Surg Oncol. 2016; 14(1):4.
26. Breer S, Brunkhorst T, Beil FT, et al. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT. Bone. 2014; 64:222–7.
27. Umphrey LG, Whitaker MD, Bosch EP, Cook CB. Clinical and bone density outcomes of tumor-induced osteomalacia after treatment. Endocr Pract. 2007; 13(5):458–62.
28. Rendina D, De Filippo G, Tauchmanova L, et al. Bone turnover and the osteoprotegerin-RANKL pathway in tumor-induced osteomalacia: a longitudinal study of five cases. Calcif Tissue Int. 2009; 85(4):293–300.
29. Chong WH, Andreopoulou P, Chen CC, et al. Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J Bone Miner Res. 2013; 28(6):1386–98.
30. Shane E, Parisien M, Henderson JE, et al. Tumor-induced osteomalacia: clinical and basic studies. J Bone Miner Res. 1997; 12(9):1502–11.
31. Misof BM, Roschger P, Klaushofer K, et al. Increased bone matrix mineralization in treatment-naive children with inflammatory bowel disease. Bone. 2017; 105:50–6.
32. Hartmann K, Koenen M, Schauer S, et al. Molecular actions of glucocorticoids in cartilage and bone during health, disease, and steroid therapy. Physiol Rev. 2016; 96(2):409–47.
33. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res. 2001; 16(1):97–103.
34. Dempster DW, Roschger P, Misof BM, et al. Differential effects of teriparatide and zoledronic acid on bone mineralization density distribution at 6 and 24 months in the SHOTZ study. J Bone Miner Res. 2016; 31(8):1527–35.
35. Misof BM, Roschger P, Gabriel D, et al. Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort. J Bone Miner Res. 2013; 28(3):442–8.
36. Cheung M, Roschger P, Klaushofer K, et al. Cortical and trabecular bone density in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 2013; 98(5):E954–61.
37. Nawrot-Wawrzyniak K, Varga F, Nader A, et al. Effects of tumor-induced osteomalacia on the bone mineralization process. Calcif Tissue Int. 2009; 84(4):313–23.
38. Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017; 26(4):266–75.
39. Carpenter TO, Imel EA, Ruppe MD, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014; 124(4):1587–97.
40. Rehman MT, Hoyland JA, Denton J, Freemont AJ. Age related histomorphometric changes in bone in normal British men and women. J Clin Pathol. 1994; 47(6):529–34.